Ross Federman
About Ross Federman
Ross Federman is a Scientist II and Chief Innovation Officer at Generate:Biomedicines, co-founder of the company, and an Origination Partner at Flagship Pioneering.
Ross Federman Title and Roles
Ross Federman holds the position of Scientist II and serves as the Chief Innovation Officer at Generate:Biomedicines. As the Chief Innovation Officer, he oversees corporate strategy, platform and data strategy, and leads an innovation group called G:Labs. His role involves steering the company's innovative initiatives and driving its strategic direction.
Ross Federman Co-founder of Generate:Biomedicines
Ross Federman co-founded Generate:Biomedicines, a company that focuses on developing next-generation biopharmaceuticals. His work with the company has significantly influenced its corporate strategy and innovation trajectory. Under his leadership, Generate:Biomedicines continues to explore new frontiers in biotech to address complex medical challenges.
Ross Federman and Flagship Pioneering
Ross Federman is an Origination Partner at Flagship Pioneering, a firm dedicated to creating, resourcing, and building life sciences companies. In this role, he contributes to identifying and nurturing innovative biotech startups, fostering a fertile environment for groundbreaking scientific advancements.
Ross Federman Education and Expertise
Ross Federman received his PhD in computational and systems biology from Washington University in Saint Louis. His academic expertise is further demonstrated through his collaboration with St. Louis Children's Hospital, where he studied the effects of early life interventions on the development of the preterm infant gut microbiome and related health outcomes.
Ross Federman Achievements and Publications
Ross Federman's work has led to multiple pending patents and numerous publications in prestigious journals such as Science and Nature. He was honored in 2020 on Endpoints News' 20 under 40 list in biopharma and was listed in 2021 in Business Insider's list of 12 young serial entrepreneurs building the next generation of biotech startups.